000			01743 a2200481 4500
005			20250516002419.0
264		0	_c20110812
008			201108s 0 0 eng d
022			_a1468-3083
024	7		_a10.1111/j.1468-3083.2010.03838.x _2doi
040			_aNLM _beng _cNLM
100	1		_aPrinz, J C
245	0	0	_aCombination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial. _h[electronic resource]
260			_bJournal of the European Academy of Dermatology and Venereology : JEADV _cMay 2011
300			_a559-64 p. _bdigital
500			_aPublication Type: Journal Article; Randomized Controlled Trial
650	0	4	_aAdult
650	0	4	_aAntirheumatic Agents _xtherapeutic use
650	0	4	_aArthritis, Psoriatic _xdrug therapy
650	0	4	_aDermatologic Agents _xtherapeutic use
650	0	4	_aDouble-Blind Method
650	0	4	_aDrug Administration Schedule
650	0	4	_aEtanercept
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aImmunoglobulin G _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPsoriasis _xdrug therapy
650	0	4	_aQuality of Life
650	0	4	_aReceptors, Tumor Necrosis Factor _xtherapeutic use
650	0	4	_aSeverity of Illness Index
650	0	4	_aTreatment Outcome
700	1		_aFitzgerald, O
700	1		_aBoggs, R I
700	1		_aFoehl, J
700	1		_aRobertson, D
700	1		_aPedersen, R
700	1		_aMolta, C T
700	1		_aFreundlich, B
773	0		_tJournal of the European Academy of Dermatology and Venereology : JEADV _gvol. 25 _gno. 5 _gp. 559-64
856	4	0	_uhttps://doi.org/10.1111/j.1468-3083.2010.03838.x _zAvailable from publisher's website
999			_c20171118 _d20171118